Belgian Study to Assess the Efficacy and Safety of the RESTORER Iliac Stent for Treatment of Aorto-iliac Lesions. (BARISTA)

Belgian Study to Assess the Efficacy and Safety of the RESTORER Iliac Stent System for the Treatment of Aorto-iliac Lesions (TASC A, B, C and D).

The BARISTA study tests the safety and efficacy of the Restorer stent from the company iVascular. This stent is a medical device that is already approved for use in Europe, to treat stenotic (narrowed) iliac arteries. 200 Belgian patients from 13 different hospitals will be included in this study. Patients will be medically monitored for 2 years from the day of the study procedure. The treatment of the stenotic iliac arteries will be according to the standard of care, using the Restorer stent. This endovascular treatment consists of introducing the necessary materials in the blood vessels by a puncture in the groin under general or local anaesthesia, after which a thin plastic tube will be inserted into the femoral artery through the puncture site, until the stenotic iliac artery is reached. Medical imaging is done by angiography. The stenotic/occluded section of the artery will first be dilated by inserting and inflating a balloon. Next, the Restorer stent will be placed and, if necessary, another balloon may be inserted and inflated to allow the stent to fit nicely to the vessel wall and optimise the result. As per standard of care, follow-up will be done in the hospital after 1, 6, 12, and 24 months. During these visits, an ultrasound scan of the treated artery will be taken to evaluate the patency of the blood vessel. Also, two short questionnaires will be completed asking about the quality of life and walking difficulties. The use of medication will be recorded. If adverse events are experienced, they will be reported.

Study Overview

• Status: Active, not recruiting
• Conditions: Peripheral Arterial Disease
• Intervention / Treatment: Device: Restorer Iliac Stent System

Detailed Description

Prospective, single-arm, multicentre, physician-initiated clinical study to assess the long-term (up to 24 months) safety and efficacy of the RESTORER peripheral stent system (iVascular) for the treatment of iliac lesions in 200 subjects, in a controlled clinical setting post CE-certification when used according to the IFU with focus on the treatment of complex TASC A, B, C and D Aorto-iliac lesions. The primary endpoint of the study is freedom of any TLR, major amputation or restenosis (defined as significant stenosis on duplex ultrasound (>50%, systolic velocity ratio greater than 2.4) within 12 months. Secondary endpoints are: technical success during procedure, and during the follow-up period: primary patency, stent graft occlusion rate, ABI, freedom from target lesion revascularization, clinical success (improvement of Rutherford classification), change in walking impairment questionnaire, change in quality of life questionnaire, freedom from above-the-ankle target limb amputation, and mortality. A subanalysis will be done to compare the results using the TASC classification, lesion location (AIE, AIC, bilateral, kissing configuration), gender, diabetes mellitus and Rutherford in terms of patency, frequency of TLR and clinical outcome at 12 and 24 months.

• Study Type: Interventional
• Enrollment (Estimated): 131
• Phase: Not Applicable

Contacts and Locations

Study Locations

• Belgium
  • Aalst, Belgium, 9300
    • O.L.V. Hospital
  • Antwerp, Belgium, 2650
    • UZA
  • Antwerp, Belgium, 2610
    • GZA Ziekenhuizen
  • Bonheiden, Belgium, 2820
    • Imelda Hospital
  • Dendermonde, Belgium, 9200
    • A.Z. Sint-Blasius
  • Genk, Belgium, 3600
    • Z.O.L.
  • Kortrijk, Belgium
    • Az Groeninge
  • Liège, Belgium, 4000
    • Chu Liege
  • Tienen, Belgium, 3300
    • R.Z. Heilig Hart
  • Vilvoorde, Belgium, 1800
    • A.Z. Jan Portaels
  • Limburg
    • Hasselt, Limburg, Belgium, 3500
      • Jessa
  • Oost-Vlaanderen
    • Ghent, Oost-Vlaanderen, Belgium, 9000
      • AZ Maria Middelares
    • Sint-Niklaas, Oost-Vlaanderen, Belgium, 9100
      • Vitaz
  • West-Vlaanderen
    • Brugge, West-Vlaanderen, Belgium, 8000
      • AZ Sint Jan Brugge

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria: 1. Males or non-pregnant females ≥ 18 years of age at the time of consent. Females of childbearing potentials have a negative pregnancy test <7 days before the procedure and are willing to use a reliable method of birth control for the duration of study participation. Female participants will be exempted from this requirement in case they are sterile, infertile or have been post-menopausal for at least 12 months.

2. Patient (or their legal representative) understands the nature of the procedure and provides written informed consent, prior to enrolment in the study.

3. Patient presenting with a stenotic or occlusive lesion at the Aorto-iliac arteries suitable for stenting with the Restorer stent (iVascular) (on indication for primary stenting, based on the discretion of the investigator). This lesion is corresponding to the CE-mark indications/contra-indications and according to the current medical guidelines for minimally invasive peripheral interventions.

4. Estimated life expectancy ≥ 2 years. 5. Patient presenting a score from 2 to 4 following Rutherford classification. 6. Patient is willing to comply with specified follow-up evaluations at the specified times for the duration of the study.

7. The target lesion has angiographic evidence of stenosis or restenosis >50% or occlusion which can be passed with standard guidewire manipulation.

8. There is angiographic evidence of a patent Common and Deep Femoral Artery.

-

Exclusion Criteria: 1. Patients with a history of coagulation disorders, 2. Presence of an aneurysm immediately adjacent of the site of stent implantation, 3. Extension of more than 1cm in distal aorta, 4. Extension into CFA, 5. Fresh thrombus formation, 6. Acute limb ischemia, defined as symptom onset during less than 14 days prior to the index procedure, 7. Any systemic infection or immunocompromised state. Patients with an ascending infection/deep foot infection or abscess/white blood count (WBC)≥12.000/or febrile state or CRP>5mg/L, 8. Existing stent implant in the target vessel, 9. Use of alternative therapies: atherectomy, cutting/scoring balloons, laser, … 10. Known coagulopathy, hypercoagulable state, bleeding diathesis, other blood disorder, or a platelet count less than 80.000/µL or greater than 500.000/µL, 11. Any subject in which antiplatelet, anticoagulant or thrombolytic therapy is contraindicated, 12. Known hypersensitivity or contraindication to the stent material (CoCr L605), 13. Has other comorbidities that, in the opinion of the investigator, would preclude them from receiving this treatment and/or participating in study-required follow-up, 14. Known hypersensitivity or allergy to contrast agents that cannot be medically managed, 15. Inadequate inflow lesion treatment (>30% residual stenosis), 16. Subject has IFU listed contraindication(s).

-

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Restorer Iliac Stent System; RESTORER Iliac Stent system for the treatment of Aorto-iliac lesions (TASC A, B, C and D) according to IFU	Device: Restorer Iliac Stent System; Not applicable (only one intervention)

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Freedom from TLR	Freedom from any Target Lesion Revascularization (TLR) at 12 months	12 months
Freedom from major amputation	Freedom from amputation above the ankle	12 months
Freedom from restenosis	No significant stenosis on duplex ultrasound (>50% stenosis or systolic velocity ratio greater than 2.4)	12 months

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Technical success	final residual angiographic stenosis <30%	1 month
Primary patency rate	lack of restenosis and no need for reintervention of the target lesion	6, 12, and 24 months
Stent graft occlusion rate	Presence or absence of occlusion	1, 6, 12, and 24 months
ABI	comparison of Ankle Brachial Index at follow-up compared to baseline ABI	6, 12, and 24 months
Freedom from Target Lesion Revascularization	freedom from repeated intervention to maintain or re-establish patency within the region of the treated arterial vessel plus 5mm proximal and distal to the treated lesion edge	12 and 24 months
Clinical improvement of at least one Rutherford classification	Clinical improvement of at least one Rutherford classification (RCC) compared to pre-procedure RCC	baseline, 6, 12, 24 months
Change in Quality of Life	Change in Quality-of-Life Questionnaire (EQ5D) at follow-up, compared to baseline	baseline, 6, 12, and 24 months
Limb salvage	Freedom from any above-the-ankle target limb amputation	6, 12, 24 months

Collaborators and Investigators

• Sponsor: ID3 Medical

Study record dates

Study Major Dates

• Study Start (Actual): June 13, 2022
• Primary Completion (Estimated): July 31, 2025
• Study Completion (Estimated): December 31, 2025

Study Registration Dates

• First Submitted: January 19, 2022
• First Submitted That Met QC Criteria: March 14, 2022
• First Posted (Actual): March 23, 2022

Study Record Updates

• Last Update Posted (Actual): October 16, 2024
• Last Update Submitted That Met QC Criteria: October 14, 2024
• Last Verified: October 1, 2024

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Cardiovascular Diseases; Vascular Diseases; Arteriosclerosis; Arterial Occlusive Diseases; Atherosclerosis; Peripheral Arterial Disease; Peripheral Vascular Diseases
• Other Study ID Numbers: BARISTA protocol v3.0 20230405

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No